PhosPrint P.C.
Dirk Groenewegen is a seasoned professional in business development within the regenerative medicine and cell & gene therapy sectors, currently serving as Managing Director at Cells4Therapy since January 2017. Groenewegen possesses extensive expertise in market transfer, intellectual property strategies, and funding avenues such as non-dilutive funding, equity investment, and venture capital across the Benelux, Germany, UK, and US. Additionally, Groenewegen holds positions as a Strategic Advisor at Limula and a Mentor at Stichting O3NL, which aids emerging entrepreneurs. Previously, Groenewegen was the CEO and Board Director of Glycostem Therapeutics from September 2005 to December 2017 and is also a Business Advisor for PhosPrint P.C. Dirk Groenewegen earned an M.Sc. in Chemical Engineering from Delft University of Technology and a Dr. in Microbiology from the University of Hamburg, complemented by a course in Pharma-Biotech Product & Company Valuation from CELforPharma.
This person is not in any teams
This person is not in any offices
PhosPrint P.C.
PhosPrint P.C. is located at the Attika Technology Park "Lefkippos" and was founded in 2019. PhosPrint’s laser bioprinting technology enhances the capabilities of modern bioprinting, enabling the transfer of cells with 100% viability and the development of antibody microarrays and other bioinks for a wide range of applications.